Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.
Patel, Sandip Pravin
Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. [electronic resource] - Cancer immunology, immunotherapy : CII Jun 2013 - 1011-9 p. digital
Publication Type: Journal Article
1432-0851
10.1007/s00262-013-1420-z doi
Animals
Antibodies, Monoclonal--immunology
Antibody-Dependent Cell Cytotoxicity--immunology
Antigens, Neoplasm--immunology
Antineoplastic Agents--immunology
Cell Line, Tumor
Colorectal Neoplasms--drug therapy
Disease Models, Animal
Female
Humans
Male
Mice
Mucin 5AC--immunology
Neoplasms--drug therapy
Pancreatic Neoplasms--drug therapy
Protein Binding--immunology
Recombinant Fusion Proteins
Tumor Burden--drug effects
Xenograft Model Antitumor Assays
Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. [electronic resource] - Cancer immunology, immunotherapy : CII Jun 2013 - 1011-9 p. digital
Publication Type: Journal Article
1432-0851
10.1007/s00262-013-1420-z doi
Animals
Antibodies, Monoclonal--immunology
Antibody-Dependent Cell Cytotoxicity--immunology
Antigens, Neoplasm--immunology
Antineoplastic Agents--immunology
Cell Line, Tumor
Colorectal Neoplasms--drug therapy
Disease Models, Animal
Female
Humans
Male
Mice
Mucin 5AC--immunology
Neoplasms--drug therapy
Pancreatic Neoplasms--drug therapy
Protein Binding--immunology
Recombinant Fusion Proteins
Tumor Burden--drug effects
Xenograft Model Antitumor Assays